These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2530792)

  • 1. Regional distribution of serotonergic pre- and postsynaptic markers in human brain.
    Laruelle M; Maloteaux JM
    Acta Psychiatr Scand Suppl; 1989; 350():56-9. PubMed ID: 2530792
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of 3H-paroxetine as a radioligand for in vivo study of 5-hydroxytryptamine uptake sites in mouse brain.
    Hashimoto K; Goromaru T
    Radioisotopes; 1990 Aug; 39(8):335-41. PubMed ID: 2146707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites.
    Haddock RE; Johnson AM; Langley PF; Nelson DR; Pope JA; Thomas DR; Woods FR
    Acta Psychiatr Scand Suppl; 1989; 350():24-6. PubMed ID: 2530779
    [No Abstract]   [Full Text] [Related]  

  • 4. Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites.
    Laruelle M; Vanisberg MA; Maloteaux JM
    Biol Psychiatry; 1988 Jul; 24(3):299-309. PubMed ID: 2969755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ability of charcoal to prevent absorption of paroxetine.
    Greb WH; Buscher G; Dierdorf HD; von Schrader HW; Wolf D
    Acta Psychiatr Scand Suppl; 1989; 350():156-7. PubMed ID: 2530777
    [No Abstract]   [Full Text] [Related]  

  • 6. The pharmacokinetics of paroxetine in elderly depressed patients.
    Ghose K
    Acta Psychiatr Scand Suppl; 1989; 350():87-8. PubMed ID: 2530797
    [No Abstract]   [Full Text] [Related]  

  • 7. A pharmacokinetic dose titration study in adult and elderly depressed patients.
    Hebenstreit GF; Fellerer K; Zöchling R; Zentz A; Dunbar GC
    Acta Psychiatr Scand Suppl; 1989; 350():81-4. PubMed ID: 2530795
    [No Abstract]   [Full Text] [Related]  

  • 8. The pharmacokinetics of paroxetine in the elderly.
    Bayer AJ; Roberts NA; Allen EA; Horan M; Routledge PA; Swift CG; Byrne MM; Clarkson A; Zussman BD
    Acta Psychiatr Scand Suppl; 1989; 350():85-6. PubMed ID: 2530796
    [No Abstract]   [Full Text] [Related]  

  • 9. The pharmacokinetics of paroxetine in patients with liver cirrhosis.
    Krastev Z; Terziivanov D; Vlahov V; Maleev A; Greb WH; Eckl KM; Dierdorf HD; Wolf D
    Acta Psychiatr Scand Suppl; 1989; 350():91-2. PubMed ID: 2530799
    [No Abstract]   [Full Text] [Related]  

  • 10. Paroxetine plasma levels: lack of correlation with efficacy or adverse events.
    Tasker TC; Kaye CM; Zussman BD; Link CG
    Acta Psychiatr Scand Suppl; 1989; 350():152-5. PubMed ID: 2530776
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.
    Bannister SJ; Houser VP; Hulse JD; Kisicki JC; Rasmussen JG
    Acta Psychiatr Scand Suppl; 1989; 350():102-6. PubMed ID: 2530759
    [No Abstract]   [Full Text] [Related]  

  • 12. The pharmacokinetics of paroxetine in renal impairment.
    Doyle GD; Laher M; Kelly JG; Byrne MM; Clarkson A; Zussman BD
    Acta Psychiatr Scand Suppl; 1989; 350():89-90. PubMed ID: 2530798
    [No Abstract]   [Full Text] [Related]  

  • 13. Absorption of paroxetine under various dietary conditions and following antacid intake.
    Greb WH; Brett MA; Buscher G; Dierdorf HD; von Schrader HW; Wolf D; Mellows G; Zussman BD
    Acta Psychiatr Scand Suppl; 1989; 350():99-101. PubMed ID: 2530802
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinical pharmacology of paroxetine in healthy subjects.
    Raptopoulos P; McClelland GR; Jackson D
    Acta Psychiatr Scand Suppl; 1989; 350():46-8. PubMed ID: 2530788
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.
    Greb WH; Buscher G; Dierdorf HD; Köster FE; Wolf D; Mellows G
    Acta Psychiatr Scand Suppl; 1989; 350():95-8. PubMed ID: 2530801
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition and dissociation of [3H]-paroxetine binding to human platelets.
    Andersson A; Marcusson J
    Neuropsychobiology; 1989; 22(3):135-40. PubMed ID: 2535005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline.
    Kuhs H; Schlake HP; Rolf LH; Rudolf GA
    Acta Psychiatr Scand; 1992 May; 85(5):364-9. PubMed ID: 1534961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symmetrical hemispheric distribution of 3H-paroxetine binding sites in postmortem human brain from controls and suicides.
    Lawrence KM; De Paermentier F; Cheetham SC; Crompton MR; Katona CL; Horton RW
    Biol Psychiatry; 1990 Sep; 28(6):544-6. PubMed ID: 2145984
    [No Abstract]   [Full Text] [Related]  

  • 19. Affinity of (+/-)-pindolol, (-)-penbutolol, and (-)-tertatolol for pre- and postsynaptic serotonin 5-HT(1A) receptors in human and rat brain.
    Castro ME; Harrison PJ; Pazos A; Sharp T
    J Neurochem; 2000 Aug; 75(2):755-62. PubMed ID: 10899952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological effects of paroxetine after repeated administration to animals.
    Nelson DR; Thomas DR; Johnson AM
    Acta Psychiatr Scand Suppl; 1989; 350():21-3. PubMed ID: 2530778
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.